Article
A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Aug 2007
Ohnishi Tetsuo, Yamada Kazuo, Ohba Hisako, Iwayama Yoshimi, Toyota Tomoko, Hattori Eiji, Inada Toshiya, Kunugi Hiroshi, Tatsumi Masahiko, Ozaki Norio, Iwata Nakao, Sakamoto Kaoru, Iijima Yoshimi, Iwata Yasuhide, Tsuchiya Kenji J, Sugihara Genichi, Nanko Shinichiro, Osumi Noriko, Detera-Wadleigh Sevilla D, Kato Tadafumi, Yoshikawa Takeo
Abstract excerpt
Lithium is an effective mood stabilizer for bipolar disorder patients and its therapeutic effect may involve inhibition of inositol monophosphatase activity. In humans, the enzyme is encoded by two genes, IMPA1 and IMPA2. IMPA2 maps to 18p11.2, a genomic interval for which evidence of linkage to bipolar disorder has been supported by several reports. We performed a genetic association study in Japanese cohorts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
